Merck to Merge with Schering-Plough in a US$41.1 B deal

By Taskin Ahmed

Pharma Deals Review: Vol 2009 Issue 3 (Table of Contents)

Published: 9 Mar-2009

DOI: 10.3833/pdr.v2009.i3.1072     ISSN: 1756-7874

Section: Mergers & Acquisitions

Fulltext:

Abstract

Merck & Co and Schering-Plough have announced that they are to merge in a deal worth US$41.1 B. It’s a deal that has been long speculated because of their existing marketing relationships over Zetia® and Vytorin® and the opportunity of potential cost savings. The combined company will generate sales of US$47 B. The deal will diversify Merck’s portfolio of drugs and double its late stage pipeline to 18 developments. Merck’s CEO, Richard Clark, will head the merged company with Merck shareholders owning a 68% stake. Schering-Plough generates 70% of its revenue outside of the US which will accelerate Merck’s international growth.

Copyright: © IQVIA 2018

PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details